Die Zuteilungsregeln für die zweite Emissionshandelsperiode Teil 1: Industrie- vs. Energieanlagen

Die erste Emissionshandelsperiode geht am 31.12.2007 zu Ende, die zweite beginnt am 1.1.2008. Damit wird das System fortgesetzt, welches den Betrieb von CO2-emittierenden Anlagen an die Abgabe von Emissionshandelsberechtigungen knüpft. Diese Berechtigungen wurden in der ersten Handelsperiode vollst?ndig kostenlos von der Deutschen Emissionshandelsstelle beim Umweltbundesamt nach komplizierten Regelungen verteilt. Dabei wurde einheitlich ein Erfüllungsfaktor von 0,9709 zugrunde gelegt. Nach ihm richtet sich, in welchem Ma?e die einzelnen Anlagenbetreiber ihre Reduktionsverpflichtungen erfüllen müssen. Nunmehr wurden zwar die Regeln deutlich vereinfacht. Ein neuer fester Erfüllungsfaktor gilt aber nicht mehr nahezu fl?chendeckend, sondern nur noch für Industrieanlagen. Energieanlagen unterliegen einer in ihrer H?he noch ungewissen anteiligen Kürzung. Die Zuteilungsregeln für bis zum 31.12.2002 in Betrieb genommene Anlagen sind nunmehr von einer Zweiteilung zwischen Industrie- und Energieanlagen gepr?gt: Grandfathering einerseits, Benchmark-Ansatz andererseits. Allerdings gibt es auch Gemeinsamkeiten, n?mlich für H?rtef?lle, Kapazit?tserweiterungen und Kleinanlagen. Neu ist die teilweise Ver?u?erung.     

Justice for All: Putting Victims at the Heart of Criminal Justice?

This article considers the claim in the government's White Paper, Justice for All , to put victims and witnesses at the heart of the criminal justice system and argues that there is an unresolved tension within the paper between instrumentalist crime control concerns and intrinsic concerns for the rights of victims and witnesses. It is argued that many of the proposals now contained in the latest Criminal Justice Bill are so preoccupied with rebalancing the system away from offenders that they risk doing injustice to defendants with little tangible benefit to victims and witnesses in terms of rights and remedies.     

Toxicological analysis of a fatal baclofen (Lioresal) ingestion

A fatality following ingestion of the drug baclofen (Lioresal) is described. Baclofen was identified in urine by gas chromatography/mass spectrometry. After derivatization with trinitrobenzene sulfonic acid, baclofen was quantitated in serum and urine by high-performance liquid chromatography. The concentration of baclofen was 17 mg/L in serum and 760 mg/L in urine collected approximately 12 h after the overdose. To our knowledge, this is only the second reported fatality involving a baclofen overdose. The previous case did not include quantitation of baclofen in any biological fluid.     

A modification of the microplate method for reverse ABO typing of bloodstains and additional validation studies

The results of additional validation studies of a sensitive microplate hemagglutination assay for ABO reverse grouping of bloodstains are presented. The results of the validation study demonstrate the reliability of the microplate assay for use in routine serological casework. Based on these studies, the microplate assay has now replaced the Lattes crust test for ABO reverse grouping of bloodstains in the FBI Laboratory.     

Acidic and neutral drugs screen in blood with quantitation using microbore high-performance liquid chromatography–diode array detection and capillary gas chromatography–flame ionization detection

Blood previously acidified with aqueous saturated ammonium chloride solution was extracted with ethyl acetate. The dried extract was subjected to acetonitrile–hexane partition. The acetonitrile portion was analysed for the presence of acidic and neutral drugs by HPLC–DAD (200 mm×2.1 mm I.D. microbore ODS-Hypersil column) and GC–FID (25 m narrow-bore×0.25 mm I.D. HP-5 column with 0.33 μm film thickness). The protocol was found to be suitable for both clinical toxicology (including emergency toxicology) and postmortem toxicology. At least 66 drugs of interest were unequivocally identified by RRTs (HPLC) and UV spectra (DAD) match while another 12 were unequivocally identified by double RRTs match (HPLC and GC). Quantitation was facilitated by incorporating calibration blood standards in each assay batch. The five drugs most commonly encountered in clinical blood specimens (1150 cases) were: paracetamol (47.4% of the cases); chlormezanone (6.6%), theophylline (1.74%), naproxen (1.65%) and mefenamic acid (1.56%). The following drugs were detected in toxicologically significant quantities in postmortem blood specimens (245 cases): phenobarbitone (1.22% of the cases), naproxen (0.82%), chlormezanone (0.82%), theophylline (0.82%), carbamazepine (0.41%) and paracetamol (0.41%).